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Abstract
Epidemiological studies suggest an inverse relationship between helminth infections and allergic disease, and several
helminth-derived products have been shown to suppress allergic responses in animals. This study was undertaken to
evaluate the effect of a crude extract of Caenorhabditis elegans on allergic airway inflammation in a murine model of
asthma. Allergic airway inflammation was induced in BALB/c mice by sensitization with ovalbumin. The effect of the C.
elegans crude extract on the development of asthma and on established asthma was evaluated by analyzing airway
hyperresponsiveness, serum antibody titers, lung histology and cell counts and cytokine levels in the bronchoalveolar
lavage fluid. The role of IFN-c in the suppression of asthma by the C. elegans crude extract was investigated in IFN-c
knockout and wild-type mice. When mice were sensitized with ovalbumin together with the crude extract of C. elegans,
cellular infiltration into the lung was dramatically reduced in comparison with the ovalbumin-treated group. Treatment of
mice with the C. elegans crude extract significantly decreased methacholine-induced airway hyperresponsiveness and the
total cell counts and levels of IL-4, IL-5 and IL-13 in the bronchoalveolar lavage fluid but increased the levels of IFN-c and IL-
12. Sensitization with the C. elegans crude extract significantly diminished the IgE and IgG1 responses but provoked
elevated IgG2a levels. However, the suppressive effect of the C. elegans crude extract was abolished in IFN-c knockout mice,
and the Th2 responses in these mice were as strong as those in wild-type mice sensitized with ovalbumin. The crude extract
of C. elegans also suppressed the airway inflammation associated with established asthma. This study provides new insights
into immune modulation by the C. elegans crude extract, which suppressed airway inflammation in mice not only during the
development of asthma but also after its establishment by skewing allergen-induced Th2 responses to Th1 responses.
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Introduction
The incidence of allergic diseases such as asthma, allergic
rhinitis and eczema has steadily increased during the recent
decades, especially in developed countries or urban areas of
developing countries where helminth infections are rare or under
control [1,2]. Although allergic diseases and helminth infections
both illicit Th2 responses, helminths have been known to provoke
anti-inflammatory responses rather than allergic reactions in
humans and animals [1,3,4]. A significant amount of epidemio-
logical evidence from human field studies has suggested the
existence of an inverse relationship between helminth infections
and asthma and allergic sensitization [5–8]. However, other
studies have reported no protective effects or enhanced allergic
sensitization in individuals infected with parasites [9–11].
Experimental studies using animal models have also shown
varying effects of parasite infection on the protection of the host
against airway inflammation and allergic disease [1]. Infection
with Strongyloides stercoralis or Nippostrongylus brasiliensis in mice
suppressed experimental airway inflammation [12,13], whereas
Toxocara canis infection exacerbated the allergic responses to
ovalbumin (OVA) in mice [14]. Schistosoma mansoni infection in
mice caused different responses to an allergen depending on the
production of eggs within the host; chronic infection with male
and female worms aggravated OVA-induced airway hyperrespon-
siveness (AHR), but experimental infection with male schistosomes
only protected mice from AHR [15]. This conflicting association
between helminth infections and allergic diseases may be the result
of several factors, including the species of parasite, the worm
burden, the frequency and duration of infection and the timing of
infection [9,14].
Recently, helminth therapy has been used to ameliorate allergic
or inflammatory diseases [16–19], and studies have reported
promising outcomes, especially in the treatment of inflammatory
bowel disease [18,19]. However, the use of helminths for the
treatment of inflammatory diseases has several potential side
effects, including iatrogenic infection, general immune suppres-
sion, anaphylactic or atopic reactions and cross-reactivity with
allergens [1]. Additional limitations of helminth therapy may
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larvae, the high cost of the therapy and poor patient compliance
with consuming eggs or worms as therapeutic agents. An
alternative solution to overcome these prospective problems would
be the use of helminth-derived products that have anti-allergic or
anti-inflammatory properties [16]. Several helminth-derived
products that are known to alter the immune responses of the
host and to have therapeutic potential for inflammatory diseases
have been suggested based on data from animal models of human
diseases [1,16,20].
Asthma is a complex disorder associated with Th2 immune
responses directed to allergens and is characterized by airway
inflammation, AHR, variable airflow obstruction and airway
remodeling [21–23]. The mainstay of asthma treatment consists of
inhaled or oral corticosteroids and long-acting b2-adrenoceptor
agonists; however, these treatments are not curative, and
symptoms return soon after treatment termination [21]. Reducing
or eliminating allergen-specific Th2 responses in the early stage of
asthma may lead to disease remission, which suggests that this may
be one potential strategy for the development of new drugs [21].
This study was undertaken to evaluate the effects of a crude extract
of Caenorhabditis elegans (CEC) on the development of OVA-induced
asthma in a murine model. We found that CEC strongly
suppressed airway inflammation not only during the development
of asthma but also after the establishment of asthma in mice and
that IFN-c was the most important cytokine in the CEC-mediated
suppression of asthma. This study provides new insights for
understanding immune modulation by C. elegans-derived products
as well as the potential application of these products as a modality
for asthma treatment.
Materials and Methods
Ethics Statement
The protocols of animal experiments were reviewed and
approved by the Institute of Laboratory Animal Resources of
Seoul National University (Permit Number: SNU-080718-1,
SNU-081008-2 and SNU-090624-9).
Animals
Seven-week-old female BALB/c mice were used in this study.
Wild-type BALB/c mice were obtained from KoaTech (Gyonggi-
do, Korea), and IFN-c knockout (KO) mice on a BALB/c
background were purchased from the Jackson Laboratory (Bar
Harbor, ME, USA). The animals were maintained at the clean
barrier animal facilities at the Seoul National University College of
Medicine under specific pathogen-free conditions.
Experimental groups
The animals were divided into three to five groups, depending
on the experimental protocol. Each group consisted of five mice.
To investigate the effects of CEC on the development of asthma,
mice were divided into the following three groups: a phosphate-
buffered saline (PBS)-treated group (PBS), an OVA-treated group
(OVA) and a group of mice sensitized with OVA and CEC
(OVA+CEC) (Exp. 1). For the experiment designed to observe the
role of IFN-c in the effect that CEC has on asthma development,
IFN-c KO and wild-type mice were each divided into the
following two groups: an OVA-treated group and an OVA+CEC-
treated group (Exp. 2). The effects of CEC were also investigated
in mice with established asthma using a different CEC treatment
regimen and the experimental groups were as follows: a PBS-
challenged group, an OVA-challenged group, groups challenged
with a single dose of 50 mg (CEC M50) or 100 mg (CEC M100) or
25 mg weekly for one month (CEC W25) (Exp. 3).
Preparation of C. elegans crude extract
The C. elegans N2 strain was grown in media supplemented with
Escherichia coli OP50 as a food source. The worms were incubated
at room temperature for six days. Adult worms were isolated,
washed three times in sterile distilled water and homogenized in
PBS with a sonicator while on ice. Following the centrifugation of
the worm homogenate, the supernatant was passed through a
0.45-mm filter for sterilization and was then used as the crude
extract of C. elegans. To eliminate endotoxin contamination, CEC
preparations were passed through Detoxi-Gel Endotoxin Remov-
ing Gel AffinityPak pre-packed columns (Thermo Scientific Pierce
Protein Research Products, Rockford, IL, USA).
Sensitization and challenge protocol
For Exp. 1 and 2, mice in the OVA group were sensitized with
75 mg OVA (Sigma-Aldrich, St Louis, MO, USA) in 3 mg
aluminum hydroxide (alum, Sigma-Aldrich) by intraperitoneal
injections on days 0 and 7. The OVA+CEC group was sensitized
with 10 mg CEC together with alum-precipitated OVA, and the
PBS group was sensitized with PBS-alum. On days 14, 15, 21 and
22, mice were intranasally challenged with 50 mg OVA. On day
23, AHR was determined after the mice were anesthetized with an
intraperitoneal injection of zoletile (Virbac Laboratories, Carros,
France). Mice were sacrificed for the collection of BAL fluid, sera
and lungs on day 24.
For Exp. 3, asthma was induced in mice by sensitization and
challenge with OVA using the same protocol as Exp. 1, except for
PBS group sensitized and challenged with PBS. AHR was
measured after the last challenge with OVA at week 3 to confirm
the establishment of asthma. Following stabilization, the mice were
divided into four groups and intranasally challenged with either
PBS, OVA or CEC at various doses and intervals: i.e., a single
dose of 50 mg (CEC M50) or 100 mg (CEC M100) or 25 mg weekly
for one month (CEC W25). At week 8, the methacholine-induced
AHR was measured, and then the mice were sacrificed for serum
and BAL collection.
Airway hyperresponsiveness measurement
The methacholine (acetyl-b-methyl-choline chloride; Sigma)-
induced AHR for Exp. 1 was evaluated using a computer-
controlled animal ventilator system after the last challenge with
OVA, as previously described [24]. Mice were anesthetized with
zoletile, tracheostomized and connected to the flexiVent system
(SCIREQ, Montreal, QC, Canada). Baseline lung mechanics were
measured following the ultrasonic nebulization of PBS into the
airways, and increasing does of methacholine (6.25, 12.5 and
25 mg/ml) were subsequently nebulized into the lungs of mice to
measure AHR.
For Exp. 2 and 3, the methacholine-induced AHR was assessed
using a whole-body plethysmograph (Allmedicus, Anyang,
Gyonggi-do, Korea) 24 hr after the final challenge with OVA,
as previously described [25]. Enhanced pause (Penh) values were
measured by nebulizing methacholine into the airways at
concentrations of 6.25, 12.5 and 25 mg/ml.
Bronchoalveolar lavage and total and differential cell
counts
The tracheas of anesthetized mice were cannulated, and the
lungs were lavaged three times with 0.5 ml sterile PBS. A total of
1.4 ml BAL fluid was collected and centrifuged at 4006 g for
C. elegans Extracts’ Effect on Airway Inflammation
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cytokine assays, and the cell pellets from the BAL fluid were
suspended in 100 ml PBS for the total and differential cell counts.
The total number of inflammatory cells in the BAL fluid was
counted using a hemocytometer. For the differential counts, the
cells in the BAL fluid were centrifuged onto slides, and the
cytospin preparations were stained with Giemsa. One hundred
cells were counted in randomly selected fields, and differential cell
counts were presented as an average of three independent counts.
Lung histology
The lungs were removed from the mice following the collection
of the BAL fluid and were then fixed in 10% phosphate-buffered
formalin for 24 hr. The tissues were embedded in paraffin and cut
into 3–5 mm sections. Histopathological observations were made
by light microscopy after the sections were stained with
hematoxylin and eosin.
Figure 1. The suppressive effect of the crude extract of Caenorhabditis elegans (CEC) on the development of airway inflammation.
Mice were sensitized with PBS, OVA or OVA+CEC by intraperitoneal injections on days 0 and 7, and then intranasally challenged with OVA on days 14,
15, 21 and 22. AHR was determined on day 23 and mice were sacrificed for the collection of BAL fluid, sera and lungs on day 24. (A) Histopathological
observation of the lungs. H&E,6100. (B) Total cell counts in the BAL fluid. (C) Differential cell counts of BAL cells. (D) Airway hyperresponsiveness to
increasing concentration of methacholine presented as airway resistance. Data are presented as the mean 6 SD from a single experiment
representative of three separate experiments. PBS (n=5), mice sensitized with PBS and challenged with OVA; OVA (n=5), mice sensitized and
challenged with OVA; OVA+CEC (n=5), mice sensitized with OVA and CEC and challenged with OVA.*, P,0.01. **, P,0.05.
doi:10.1371/journal.pone.0035447.g001
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The cytokine levels in the BAL fluid were measured using
commercial sandwich ELISA kits for IL-4, IL-5, IL-10, IL-12p70,
IL-13 and IFN-c, according to the manufacturer’s instructions
(eBioscience, Inc., San Diego, CA, USA). The detection limits for
each cytokine were 4 pg/ml for IL-4, IL-5 and IL-13, 15 pg/ml
for IL-12p70 and IFN-c and 30 pg/ml for IL-10.
Measurement of serum antibody levels
Blood was drawn from anesthetized mice by cardiac puncture,
and sera were collected and stored at 220uC until use. The serum
levels of the total and OVA-specific IgE and IgG subtypes were
measured by sandwich ELISA, according to the manufacturer’s
instructions (Bethyl Laboratories, Inc., Montgomery, TX, USA).
The IgE, IgG1 and IgG2a levels were determined based on
standard curves generated from known amounts of mouse IgE or
IgG (PharMingen, San Diego, CA, USA). The detection limits
were 0.1 ng/ml for IgE and 1 ng/ml for IgG.
Statistical analysis
All data were expressed as the mean 6 SD, and statistical
significance for comparisons between groups was determined using
Student’s t-test. P-values less than 0.05 were considered statistically
significant.
Results
CEC inhibits the development of OVA-induced airway
inflammation and airway hyperresponsiveness
The airway inflammatory responses to OVA with or without
CEC treatment were evaluated in a murine model of asthma. The
intense infiltration of inflammatory cells, predominantly eosino-
phils,intothelungswasobserved near the bronchiolesandvesselsof
mice sensitized and challenged with OVA (Figure 1A). In contrast,
no inflammatory cell infiltration was observed in the lungs of mice
both immunized and challenged with PBS only. When mice were
sensitized with CEC together with OVA, the cellular infiltration
into the lungs was dramatically reduced compared to the infiltration
observed in the OVA group (Figure 1A).
The total cell counts in the BAL fluid were consistent with the
histopathological findings of airway inflammation in the experi-
mental groups. The mice in the OVA group showed the highest
total cell counts in the BAL fluid, and the majority of the
inflammatory cells were eosinophils (Figure 1B, C). However, the
total number of cells in the BAL fluid of the OVA+CEC group
was significantly decreased in comparison to the OVA group
(P,0.01) (Figure 1B, C). The eosinophil counts in the BAL fluid
were significantly lower in the CEC-treated group than in the
OVA group (P,0.01) but were still elevated compared to those in
the PBS group. In contrast, the macrophage counts were
significantly higher in the OVA+CEC group as compared to the
OVA group (P,0.01), but they were not significantly different
from the PBS group (P=0.2209) (Figure 1C).
The OVA-sensitized mice showed a significant dose-dependent
increase in methacholine-induced AHR compared with the PBS-
treated control mice (P,0.01) (Figure 1D). However, this increase
in methacholine-induced AHR in the OVA group was signifi-
cantly suppressed by CEC sensitization (P,0.01) (Figure 1D).
CEC treatment decreases allergen-induced Th2 cytokine
production but increases Th1 cytokine levels in BAL fluid
We investigated the cytokine milieu of the lungs to understand
the mechanism by which CEC suppresses allergic airway
Figure 2. Cytokine analysis of the BAL fluid. Data from individual mice are presented as arithmetic means in histograms. PBS (n=5), mice
sensitized with PBS and challenged with OVA; OVA (n=5), mice sensitized and challenged with OVA; OVA+CEC (n=5), mice sensitized with OVA and
CEC and challenged with OVA. *, P,0.01.
doi:10.1371/journal.pone.0035447.g002
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increased levels of the Th2 cytokines IL-4, IL-5 and IL-13 in
comparison to the PBS group (P,0.01). But the IFN-c level of the
OVA group was significantly lower than that of the PBS group
(P,0.01), and the IL-12 levels were equivalent between groups
(Figure 2). However, the addition of CEC treatment resulted in a
significantly reduced level of Th2 cytokines, as compared to the
OVA group (P,0.01), whereas the levels of Th1 cytokines such as
IFN-c and IL-12 were significantly higher in the OVA+CEC
group than the PBS and OVA groups (P,0.01) (Figure 2). In
contrast, no difference in IL-10 production was found between the
OVA and OVA+CEC groups (Figure 2).
CEC treatment suppresses IgE and IgG1 levels but
enhances IgG2a levels in serum
The serum levels of IgE, IgG1 and IgG2a were measured by
sandwich ELISA. Both the total IgE and OVA-specific IgE
responses were elevated in mice in the OVA group, as compared
to those in the PBS or OVA+CEC groups (Figure 3). However,
CEC treatment significantly diminished the allergic antibody
responses in the OVA+CEC group compared to the OVA-group
(total IgE, P,0.05; OVA-specific IgE, P,0.01) (Figure 3). Similar
patterns were observed regarding the serum IgG1 levels, and the
total IgG1 and OVA-specific IgG1 levels were significantly higher
in the OVA group than in the PBS or OVA+CEC groups
(P,0.01) (Figure 3). In contrast, the IgG2a level of the OVA+CEC
group was significantly higher than that of the OVA group
(P,0.01) (Figure 3).
IFN-c plays an important role in the suppressive effect
that CEC sensitization has on asthma development
To elucidate the role of IFN-c in the suppressive effect of CEC
on the development of asthma, IFN-c KO and wild-type mice
were sensitized with OVA or OVA+CEC and challenged with
OVA using the same protocol as previously described (Exp. 2).
Increased airway inflammation, as characterized by AHR and the
total cell counts of the BAL fluid including a high number of
eosinophils, was evident in wild-type mice that had been sensitized
with OVA, but these effects were significantly decreased in mice
that had been treated with CEC (Figure 4) (P,0.01). However, in
IFN-c KO mice, the suppressive effect of CEC was abolished, and
a similar degree of airway inflammation as that observed in wild-
type mice sensitized with OVA was observed in these KO mice
following OVA exposure (Figure 4). CEC sensitization suppressed
the production of IL-4, IL-5 and IL-13 in wild-type mice but failed
to suppress the production of these Th2 cytokines in IFN-c KO
mice (Figure 5A). In contrast, the levels of IFN-c and IL-12 were
significantly higher in wild-type mice sensitized with OVA+CEC
than in mice of the other three groups (P,0.01) (Figure 5A). CEC
sensitization significantly decreased the levels of total IgE and
IgG1 but increased the level of total IgG2a in wild-type mice
(P,0.01). However, the absence of IFN-c resulted in increased
Figure 3. The evaluation of serum antibody titers in mice with OVA-induced airway inflammation. The production of total (A) and OVA-
specific IgE, IgG1 and IgG2a (B) was evaluated to identify the effects of the C. elegans crude extract. Data from individual mice are presented as
arithmetic means in histograms. PBS (n=5), mice sensitized with PBS and challenged with OVA; OVA (n=5), mice sensitized and challenged with
OVA; OVA+CEC (n=5), mice sensitized with OVA and CEC and challenged with OVA. *, P,0.01. **, P,0.05.
doi:10.1371/journal.pone.0035447.g003
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CEC treatment (Figure 5B).
CEC suppresses OVA-induced airway inflammation in
established asthma
The suppressive effect of CEC on established asthma was
investigated using a different CEC treatment regimen during the 4
weeks after asthma had been established (Exp. 3). When mice were
challenged with CEC after the establishment of asthma, the airway
inflammation, including AHR and the total and differential cell
counts in the BAL fluid, was significantly decreased in a dose-
dependent manner (Figure 6A, B). Furthermore, an analysis of the
cytokines in the BAL fluid showed a decreased Th2 cytokine
response and an increased Th1 response following CEC challenge,
whereas OVA-challenged mice showed a Th2-dominant cytokine
response (Figure 6C).
Discussion
Epidemiological and experimental studies have shown the
protective effects that helminth infections have against asthma in
humans and animals. In particular, infection by intestinal
nematodes and schistosomes has been shown to be beneficial for
allergic diseases in humans [2,26]. Based on this, clinical trials
using helminths to treat immunological diseases in humans have
been implemented [16,27]. Helminth therapy using the eggs of
Trichuris suis, a pig whipworm, has been effective for the treatment
of inflammatory bowel diseases such as ulcerative colitis and
Crohn’s disease [18,19]. Furthermore, a hookworm infection
intervention study showed improved AHR among asthma patients
as compared to those in the placebo group, although this
difference was not significant [17]. However, the use of worms
for human treatment is not be entirely harmless, as one patient
with Crohn’s disease was shown to have developed an iatrogenic
infection of T. suis [28].
C. elegans was selected as a model organism in this study to
observe the effects it could have on the suppression of allergic
airway inflammation in a murine model of asthma. Because of its
well-known biology and completely sequenced genome, C. elegans is
one of the most versatile organisms for study in biomedical fields
such as neuroscience and developmental biology [29]. It has a
short lifespan of approximately 2–3 weeks and is easily cultivated
in large numbers in liquid media or on agar plates with E. coli.
Although C. elegans is a free-living, non-parasitic nematode, it could
Figure 4. The role of IFN-c in the CEC-mediated suppression of airway inflammation induced by OVA challenge in wild-type and
IFN-c KO mice. Mice were sensitized with PBS, OVA or OVA+CEC on days 0 and 7, and then challenged with OVA on days 14, 15, 21 and 22. AHR was
determined on day 23, followed by sacrifice of mice for the collection of BAL fluid, sera and lungs on day 24. The infiltration of inflammatory cells into
the lung (A), methacholine-induced airway hyperresponsiveness (B), and total (C) and differential cell counts (D) in the BAL fluid were investigated.
Wild-type OVA (n=5), wild-type mice sensitized with OVA; Wild-type OVA+CEC (n=5), wild-type mice sensitized with OVA and CEC; IFN-c KO OVA
(n=5), IFN-c KO mice sensitized with OVA; IFN-c KO OVA+CEC (n=5), IFN-c KO mice sensitized with OVA and CEC. *, P,0.01.
doi:10.1371/journal.pone.0035447.g004
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by other intestinal nematodes, if given the chance to enter a host.
Cystatins of C. elegans has been shown to increase the production of
IFN-c and IL-12 by human peripheral blood mononuclear cells
[30], and they can inhibit cathepsin B, leading to enhanced
expression of Th1 cells [31]. This finding suggests that
components of C. elegans may have an inhibitory effect on allergic
airway inflammation by enhancing the Th1 responses.
As C. elegans was cultured in media supplemented with E. coli,
CEC samples were flowed through endotoxin removing gels to
remove endotoxin by affinity chromatography, and the endotoxin
level in 10 mg CEC for sensitization of mice was determined to be
less than 1 endotoxin unit/mg. In our preliminary study, dendritic
cells stimulated in vitro by CEC produced higher amount of IL-12
than by LPS alone or together with CEC, and CEC induced IL-12
and IFN-c production in naı ¨ve mice (data not shown). Therefore,
it is considered that CEC can induce Th1 responses in mice, and
the amount of possible contamination of LPS in CEC samples is
negligible to have effects seen in this study.
Because asthma is associated with dysregulated Th2 responses,
enhanced Th1 responses may suppress the development of allergic
airway inflammation [21]. Therefore, strategies that enhance Th1
responses have been proposed as therapies for ameliorating
allergic airway inflammation. The administration of IFN-c into
Figure 5. The evaluation of cytokine secretion in the BAL fluid (A) and the antibody titers from the sera (B) of wild-type and IFN-c
KO mice. Wild-type OVA (n=5), wild-type mice sensitized with OVA; Wild-type OVA+CEC (n=5), wild-type mice sensitized with OVA and CEC; IFN-c
KO OVA (n=5), IFN-c KO mice sensitized with OVA; IFN-c KO OVA+CEC (n=5), IFN-c KO mice sensitized with OVA and CEC. *, P,0.01.
doi:10.1371/journal.pone.0035447.g005
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OVA-specific IgE responses and cutaneous reactivity to OVA, and
this administration also prevents the development of secondary
allergen sensitization even after primary allergic responses are well
established in mice [32]. Although airway inflammation and AHR
persist for 8 weeks following OVA challenge in IFN-c KO mice, 1
week of IFN-c treatment is able to reverse this asthmatic reaction,
even when the allergic airway reaction is established [33]. In the
present study, the attenuation of airway inflammation and AHR
by CEC treatment either during the development of or after the
establishment of asthma was associated with a shift from a Th2 to
a Th1 response in mice sensitized and challenged with OVA.
Figure 6. The suppressive effects of the crude extract of Caenorhabditis elegans (CEC) on established asthma in mice. Airway
inflammation has been induced in mice by sensitization and challenge with OVA using the same protocol as in Fig. 1, whereas PBS group (n=5), the
negative control group, was sensitized and challenged with PBS. The establishment of asthma was confirmed by measuring AHR after the last
challenge with OVA at week 3, and thereafter, mice were divided into four experimental groups and challenged with either OVA or various CEC
regimens. PBS group and OVA group (n=5) were intranasally challenged with PBS or OVA, respectively, at week 4 and 6. CEC M50 (n=5) and CEC
M100 (n=5) groups were intranasally challenged once with a single dose of 50 mg or 100 mg CEC at week 4. CEC W25 (n=5) group was intranasally
challenged with 25 mg of CEC weekly for one month from week 4 to week 7. At week 8, the methacholine-induced AHR was measured, and then the
mice were sacrificed for serum and BAL collection. (A) Airway hyperresponsiveness to methacholine was measured using a whole-body
plethysmograph at week 8. Data are presented as the mean 6 SD from a single experiment representative of three separate experiments. (B) Total
and differential cell counts in the BAL fluid. (C) Analysis of cytokines in the BAL fluid. Data from individual mice are presented as arithmetic means in
histograms. *, P,0.01.
doi:10.1371/journal.pone.0035447.g006
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allergen-specific antibodies and the drastically increased concen-
trations of Th1 cytokines, such as IFN-c and IL-12, were also
observed in the BAL fluid. Importantly, IFN-c KO mice exhibited
no attenuation in airway inflammation following CEC treatment,
suggesting that IFN-c plays an essential role in the CEC-mediated
inhibition of allergic airway inflammation. Therefore, the Th2-
dominant cytokine response resulting from OVA sensitization and
challenge in mice was altered to a Th1-dominant response by
CEC treatment, and this treatment led to the inhibition of asthma
in this study. However, heat-inactivated CEC did not inhibit
allergic airway inflammation, suggesting that the properties of
CEC in suppression of asthma in mice are proteinaceous (data not
shown).
In CEC-treated BALB/c mice, the number of alveolar
macrophages was significantly increased in comparison to the
group that only received OVA (Figure 1C). Alveolar macrophages,
which are the most abundant haematopoietic cells in the lung, play
an important role in pulmonary innate immunity. However, they
have also been suggested to suppress allergic asthma by secreting
soluble molecules such as IFN-c and IL-12 and/or by directly
interacting with other cells [34]. The depletion of alveolar
macrophages in OVA-sensitized mice was shown to markedly
enhance airway inflammation and AHR, and the adoptive transfer
of OVA-pulsed lung macrophages selectively promoted a Th1
response [35]. In the present study, the concentration of IL-12 and
the number of macrophages in the BAL fluid of OVA-challenged
wild-type mice were increased following CEC treatment. More-
over, IFN-c deficiency of the OVA-challenged hosts ablated these
effects. Therefore, these results suggest that CEC-induced Th1
responses may suppress the development and progression of
asthma by activating alveolar macrophages and thereby enhancing
their production of IL-12. Although the mechanism by which
CEC treatment enhances Th1 responses has not been fully
investigated, CEC seems to modulate the Th1/Th2 balance by
affecting the function of dendritic cells (DCs), as DCs cultured in
the presence of CEC produced a higher amount of IL-12 than
control DCs (data not shown).
Regarding the immunological mechanisms by which helminth
infections suppress the development of allergic responses, it has
been proposed that changes in the regulatory networks of IL-10 or
regulatory T cells (Treg cells) as well as the induction of
alternatively activated macrophages or immunosuppressive B cells
are involved [1]. For example, cystatin, the secreted product of the
rat filarial nematode Acanthocheilonema viteae, was shown to protect
mice from allergic airway inflammation and dextran sulfate
sodium-induced colitis, and this was likely due to enhanced IL-10
production by macrophages but not Treg cells [36]. IL-10
mediated suppression of allergen-induced airway eosinophilia
was observed in mice infected with N. brasiliensis 4 or 8 weeks
before OVA-airway challenge [13]. However, IL-10 may not play
a major role in our system, as no significant increase in IL-10 levels
in the BAL fluid of CEC-treated mice was observed. However,
further study is needed to clarify the role of Treg cells in the CEC-
mediated inhibition of asthma development.
This study clearly demonstrated that crude extracts of C. elegans
inhibited the development of allergen-specific Th2 responses by
shifting the Th2 response to a Th1 response and that IFN-c plays
an important role in the CEC-mediated amelioration of both
acute and established asthma. However, the Th1/Th2 balance
may be differentially modulated depending on the types of parasite
antigens present. ES-62, a phosphorylcholine-containing glyco-
protein of A. viteae, is the best-characterized immunoregulatory
molecule derived from helminths [1,20] and has been shown to
suppress airway inflammation in mice [37] and decrease the
severity and progression of collagen-induced arthritis by inhibiting
collagen-specific pro-inflammatory/Th1 cytokine release [38]. In
contrast, Ascaris suum contains two different protein components
that have opposite effects on experimental asthma in mice [39].
The allergenic protein of A. suum (APAS-3) induced Th2 responses,
such as eosinophilic infiltration into the airways and the induction
of IL-4, IL-5 and AHR, in BALB/c mice [39], whereas the
suppressive protein of A. suum (PAS-1) markedly suppressed APAS-
3-induced airway inflammation [39,40]. The components of CEC
that are responsible for the suppression of airway inflammation
observed in this study have yet to be elucidated. The possible
candidates may include cysteine protease inhibitors, chemokine
binding proteins, phosphorylcholine-containing proteins, glycans
and glycolipids [16,36].
In this study, two methods, the non-invasive whole body
plethysmography (Penh method) and the invasive technique using
a computer-controlled animal ventilator (flexiVent system), were
used to assess measure airway function in asthma-induced mice.
With advantages of decreasing the cost, time and the number of
animals required for experiments and the remarkable ease of use,
the whole body plethysmography has been widely used in the
measurement of lung function in mice [41,42]. However, many
evidences showed that Penh does not always correlate with airway
resistance and therefore, Penh is required to be confirmed by
invasive techniques [41,42]. We found that Penh correlated well
with airway resistance measured by flexiVent system in our model
system of asthma in Exp. 1 (data not shown), and therefore, the
whole body plethysmography was used to assess the airway
responsiveness in Exp. 2 and 3.
To our knowledge, this is the first report to document the
suppressive effect that C. elegans-derived extracts have on allergic
airway inflammation in a murine model of asthma. However, one
should be cautious when attempting to extrapolate data from
animal models of asthma to the human disease, and the relevance
of our observations in mice to human asthma remains to be
completely determined. Moreover, the role of Th1 cytokines,
especially IFN-c, in the development of asthma is controversial, as
conflicting evidence has suggested that it can both suppress and
enhance Th2 responses in mouse models of allergic airway
inflammation [22,33,43]. Nevertheless, the present study provides
new insights into understanding the immune modulation governed
by parasite-derived products and the development of new asthma
treatment strategies.
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